Abstract

BackgroundUse of imputed data vs observed data in long-term studies, as well as patient (pt) population evaluated (those completing randomized controlled trials [RCTs] vs all pts initiating treatment), can have...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension
Edward Keystone ... Philip Mease
Annals of the Rheumatic Diseases | VOL. 73
Edward Keystone, et. al.Edward Keystone ... Philip Mease
05 Aug 2013
Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.
Josef S Smolen ... Boulos Haraoui
Arthritis Research & Therapy | VOL. 17
Josef S Smolen, et. al.Josef S Smolen ... Boulos Haraoui
10 Sep 2015
THU0192 5-Year Results from the Rapid 1 Trial and Open-Label Extension: Long-Term Safety and Efficacy of Certolizumab Pegol in Combination with Methotrexate in the Treatment of Rheumatoid Arthritis
E Keystone ... D Van Der Heijde
Annals of the Rheumatic Diseases | VOL. 72
E Keystone, et. al.E Keystone ... D Van Der Heijde
01 Jun 2013
Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial
E C Keystone ... V Strand
Rheumatology | VOL. 51
E C Keystone, et. al.E C Keystone ... V Strand
16 May 2012
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
Expert consensus recommendations for the diagnosis and treatment of chronic non-bacterial osteitis (CNO) in adults
Elizabeth M Winter ... Anne T Leerling
Annals of the Rheumatic Diseases | VOL. -
Elizabeth M Winter, et. al.Elizabeth M Winter ... Anne T Leerling
28 Nov 2024
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial
Jinjing Liu ... Xiaofeng Zeng
Annals of the Rheumatic Diseases | VOL. -
Jinjing Liu, et. al.Jinjing Liu ... Xiaofeng Zeng
27 Nov 2024
CD-19 CAR-T cells for polyrefractory rheumatoid arthritis
Merav Lidar ... Abraham Avigdor
Annals of the Rheumatic Diseases | VOL. -
Merav Lidar, et. al.Merav Lidar ... Abraham Avigdor
27 Nov 2024
Correction: Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment
-
Annals of the Rheumatic Diseases | VOL. -
--
27 Nov 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.